menu
    • menu
    [{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and Key Oncologics Have Signed an Exclusive Agreement to Commercialize Yondelis\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Authorised Uses of Cancer Medicine Yondelis Unchanged Following Review of New Data","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis\u00ae in Turkey","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and STADA Sign Agreement to Commercialize Yondelis\u00ae (trabectedin) in the MENA Region","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"PharmaMar \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GLOBAL Sarcoma Therapy Now Approved for Australian Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Sarcoma Therapy Now Approved for New Zealand Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialise.."},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma Gets Tentative Approval for Yondelis Generic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Natco Pharma","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natco Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Natco Phar.."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis\u00ae in Latin America","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Adium Pharma","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Receives US$10 Million Milestone Payment from Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmamar Receives US$10 Million Milestone Payment from Janssen","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma Commences Yondelis\u00ae Commercialization in Canada","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"PharmaMar","sponsor":"TOYO Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Taiwan Toyo Obtains Exclusive License for New Soft Tissue Sarcoma Drug Yondelis\u00ae in Taiwan, Hong Kong and Macau","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"PharmaMar","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ TOYO Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"PharmaMar .."},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EVER Pharma gains EU Marketing Authorization for Trabectedin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Trabectedin","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Ever Pharma","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ever Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Ever Pharm.."}]

    Find Clinical Drug Pipeline Developments & Deals for Trabectedin

    Menu

    Trabectedin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ever Pharma

                            Austria arrow
                            CPhI Worldwide, Milan
                            Booth #14F8
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEver Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EVER Pharma gains EU Marketing Authorization for Trabectedin

                            Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.

                            Product Name : Trabectedin EVER Pharma

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2024

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Ever Pharma CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmamar Receives US$10 Million Milestone Payment from Janssen

                            Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cance...

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Valeo Pharma Commences Yondelis® Commercialization in Canada

                            Details : Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, that acts a DNA inhibitor. It is indicated for the treatment of of patients with...

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 06, 2023

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Specialised Therapeutics

                            Australia arrow
                            Pharmaconex 2024
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Global Sarcoma Therapy Now Approved for New Zealand Patients

                            Details : Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in ...

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 17, 2023

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmamar Receives US$10 Million Milestone Payment from Janssen

                            Details : Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cance...

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 12, 2022

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Natco Pharma

                            India arrow
                            Pharmaconex 2024
                            Not Confirmed

                            Natco Pharma

                            India arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Natco Pharma Gets Tentative Approval for Yondelis Generic

                            Details : Yondelis-Generic (trabectedin) is a DNA inhibitor, small molecule drug candidate. It is being developed for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who rece...

                            Product Name : Yondelis-Generic

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Specialised Therapeutics

                            Australia arrow
                            Pharmaconex 2024
                            Not Confirmed

                            Specialised Therapeutics

                            Australia arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GLOBAL Sarcoma Therapy Now Approved for Australian Patients

                            Details : The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or lei...

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 23, 2021

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : STADA Arzneimittel

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PharmaMar and STADA Sign Agreement to Commercialize Yondelis® (trabectedin) in the MENA Region

                            Details : PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. Yondelis® is marketed in several MENA countries f...

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 17, 2020

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : STADA Arzneimittel

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Onko Kocsel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            PharmaMar Signs a New Agreement with Onko to Commercialize Yondelis® in Turkey

                            Details : Trabectedin is currently provided by Janssen to patients in Turkey for the treatment of Soft Tissue Sarcoma and, through this license, Onko will also pursue regulatory approval for the indication of relap...

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 10, 2020

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Onko Kocsel Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed

                            PharmaMar

                            Spain arrow
                            Pharmaconex 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Adium Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis® in Latin Americ...

                            Details : Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.

                            Product Name : Yondelis

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 27, 2020

                            Lead Product(s) : Trabectedin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Partner/Sponsor/Collaborator : Adium Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth